MII IG Kerndatensatz-Modul Molekulargenetischer Befundbericht
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Molekulargenetischer Befundbericht (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example Observation: mii-exa-molgen-therapeutische-implikation-fgfr2-fusion

English

Profiles: MII PR MolGen Therapeutische Implikation version: 2027.0.0-ballot.1, Therapeutic Implication version: 3.0.0

status: Final

category: Laboratory, Genetics

code: Therapeutic Implication

subject: Anonymous Patient Female, DoB: 1964-05 ( pseudonymized (use: usual, ))

effective: 2022-11-30

performer: Practitioner Dr. Daniel Schmidt(official)

derivedFrom: Observation Genetic variant assessment

component

code: Conclusion Text

value: Hochselektiver FGFR2-Inhibitor RLY-4008 bei Patienten mit Cholangiokarzinomen und anderen soliden Tumoren, mit oder ohne FGFR- gerichtete Vortherapie.

component

code: Medication assessed [ID]

value: Fibroblasten-Wachstumsfaktor-Rezeptor (FGFR)-Tyrosinkinase-Inhibitoren

component

code: Level of evidence

value: m1c

component

code: Associated phenotype

value: Intrahepatic bile duct carcinoma (disorder)